Abstract
No public abstract is available from the verified source records.
Yifan Bi, Ziyi Xiong, Xiaolu Cui, Mo Zhang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
10.1016/s1470-2045(25)00209-8 · 2025
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
10.1158/1078-0432.ccr-25-1211 · 2025
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
10.1200/jco.23.00233 · 2023
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
10.1200/jco.19.01638 · 2020
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
10.1158/0008-5472.can-13-0992 · 2014
Targeting TREM2 on tumor-associated macrophages enhances immunotherapy
10.1016/j.celrep.2021.109844 · 2021
Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer
10.3390/ijms22158340 · 2021
Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution
10.1016/j.ccell.2024.06.003 · 2024
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy
10.1002/cac2.12596 · 2024
Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota
10.1186/s12943-024-02137-1 · 2024
Regulation of macrophage plasticity by circCCDC7 19-13 through HSP90 inhibition suppresses prostate cancer progression and metastasis: a translational study
10.1097/js9.0000000000002895 · 2025
Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?
10.3390/cancers15133473 · 2023
Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity
10.4049/jimmunol.1500959 · 2015
Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis
10.1038/s41388-019-0688-7 · 2019
Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell-Mediated Immune Suppression and Tumor Progression
10.1158/2326-6066.cir-19-0371 · 2020
Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions
10.1016/j.jlb.2025.100305 · 2025
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
10.1073/pnas.0915174107 · 2010
Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer
10.1111/iju.15378 · 2024
Dendritic cell subsets in cancer immunity and tumor antigen sensing
10.1038/s41423-023-00990-6 · 2023
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial
10.1136/jitc-2026-014803 · 2026
Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives
10.1002/cac2.12392 · 2023
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
10.1016/j.ejca.2021.09.043 · 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
10.1136/jitc-2022-004761 · 2022
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
10.1016/s1470-2045(25)00566-2 · 2026
PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice
10.1172/jci171154 · 2024
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
10.1038/nm.4308 · 2017
Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy
10.1016/j.ccell.2024.05.013 · 2024
Neutrophil plasticity in the tumor microenvironment
10.1182/blood-2018-11-844548 · 2019
Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism
10.4049/jimmunol.174.4.1783 · 2005
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
10.1016/j.annonc.2025.05.007 · 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
10.1016/j.annonc.2025.05.008 · 2025
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
10.1200/jco.18.02031 · 2019
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer
10.1016/j.ccell.2023.10.006 · 2023
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
10.1038/s41571-024-00859-1 · 2024
Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses
10.1038/s41467-023-36325-2 · 2023
Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies
10.1158/2326-6066.cir-15-0036 · 2015
Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer
10.1016/j.ccell.2022.04.011 · 2022
Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer
10.1007/s00262-014-1591-2 · 2014
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
10.1172/jci96268 · 2018
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
10.1016/j.cell.2019.10.029 · 2019
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer
10.1126/sciimmunol.ade4656 · doi-reference
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8(+) T cell-mediated ferroptosis in castration-resistant prostate cancer
10.1016/j.apsb.2021.07.016 · doi-reference
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
10.1016/j.eururo.2022.02.023 · doi-reference
Prostaglandin E(2) Inhibits Prostate Cancer Progression by Countervailing Tumor Microenvironment-Induced Impairment of Dendritic Cell Migration through LXRα/CCR7 Pathway
10.1155/2018/5808962 · doi-reference
PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction
10.1016/j.celrep.2020.108278 · doi-reference
Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor
10.3389/fimmu.2019.01399 · doi-reference
Targeting tumor-associated macrophages to synergize tumor immunotherapy
10.1038/s41392-021-00484-9 · doi-reference
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis
10.1016/j.eururo.2022.01.028 · doi-reference
AR(+)TREM2(+) macrophage induced pathogenic immunosuppression promotes prostate cancer progression
10.1038/s41467-025-62381-x · doi-reference
TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer
10.1016/j.canlet.2023.216300 · doi-reference
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
10.1126/scisignal.aad1884 · doi-reference
Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment
10.1002/pros.23929 · doi-reference
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer
10.1016/j.euo.2025.04.016 · doi-reference
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial
10.1016/j.annonc.2024.09.004 · doi-reference
The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications
10.1530/etj-22-0228 · doi-reference
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
10.1093/jnci/dju124 · doi-reference
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
10.1158/1078-0432.ccr-24-1096 · doi-reference
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
10.1038/s41392-023-01522-4 · doi-reference
PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration
10.1016/j.canlet.2022.216034 · doi-reference
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine
10.1158/0008-5472.can-09-2587 · doi-reference
YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
10.1158/0008-5472.can-24-0932 · doi-reference
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
10.1093/annonc/mdt107 · doi-reference
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
10.1158/0008-5472.can-18-1003 · doi-reference
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial
10.1038/s41467-026-72242-w · doi-reference
Immunogenic cell death and immunomodulatory effects of cabozantinib
10.3389/fonc.2021.755433 · doi-reference
Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion
10.1038/s41590-019-0346-9 · doi-reference
Cross-presentation of the oncofetal tumor antigen 5T4 from irradiated prostate cancer cells: a key role for heat-shock protein 70 and receptor CD91
10.1158/2326-6066.cir-14-0079 · doi-reference
The role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancers
10.1371/journal.pone.0054251 · doi-reference
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives
10.3109/08820139.2012.680634 · doi-reference
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
10.1038/s41591-021-01600-6 · doi-reference
Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
10.1136/jitc-2022-005060 · doi-reference
A guide to antigen processing and presentation
10.1038/s41577-022-00707-2 · doi-reference
Fibrosis and cancer: A strained relationship
10.1016/j.bbcan.2020.188356 · doi-reference
Characterization of the immune landscape in healthy mouse prostate and during prostate cancer progression
10.1080/2162402x.2025.2562220 · doi-reference
Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity
10.1158/2159-8290.cd-16-0778 · doi-reference
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity
10.1158/0008-5472.can-15-1965 · doi-reference
Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration
10.3389/fimmu.2018.02358 · doi-reference
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
10.1158/1078-0432.ccr-19-3372 · doi-reference
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
10.1158/1078-0432.ccr-24-0400 · doi-reference
Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis
10.1016/j.semcancer.2022.02.017 · doi-reference